These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25293768)

  • 1. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.
    Khellaf M; Charles-Nelson A; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Ebbo M; Le Guenno G; Cliquennois M; Salles G; Bonmati C; Teillet F; Galicier L; Hot A; Lambotte O; Lefrère F; Sacko S; Kengue DK; Bierling P; Roudot-Thoraval F; Michel M; Godeau B
    Blood; 2014 Nov; 124(22):3228-36. PubMed ID: 25293768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
    Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
    Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
    Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
    Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
    Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.
    Arnold DM; Heddle NM; Carruthers J; Cook DJ; Crowther MA; Meyer RM; Liu Y; Cook RJ; McLeod A; MacEachern JA; Mangel J; Anderson D; Vickars L; Tinmouth A; Schuh AC; Kelton JG
    Blood; 2012 Feb; 119(6):1356-62. PubMed ID: 22223819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for children with immune thrombocytopenia: a systematic review.
    Liang Y; Zhang L; Gao J; Hu D; Ai Y
    PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
    Mahévas M; Ebbo M; Audia S; Bonnotte B; Schleinitz N; Durand JM; Chiche L; Khellaf M; Bierling P; Roudot-Thoraval F; Godeau B; Michel M
    Am J Hematol; 2013 Oct; 88(10):858-61. PubMed ID: 23798363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
    Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
    Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
    Zhou H; Xu M; Qin P; Zhang HY; Yuan CL; Zhao HG; Cui ZG; Meng YS; Wang L; Zhou F; Wang X; Li DQ; Bi KH; Zhu CS; Guo CS; Chu XX; Wu QC; Liu XG; Dong XY; Li J; Peng J; Hou M
    Blood; 2015 Mar; 125(10):1541-7. PubMed ID: 25575541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.
    Bussel JB; Lee CS; Seery C; Imahiyerobo AA; Thompson MV; Catellier D; Turenne IG; Patel VL; Basciano PA; Elstrom RL; Ghanima W
    Haematologica; 2014 Jul; 99(7):1264-71. PubMed ID: 24747949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
    Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
    Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.
    Aleem A; Alaskar AS; Algahtani F; Rather M; Almahayni MH; Al-Momen A
    Int J Hematol; 2010 Sep; 92(2):283-8. PubMed ID: 20640541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
    Zhou LY; Zhang Z; Song LX; Gzhang X; Su JY; Li X; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.
    Gall B; Yee A; Berry B; Bircham D; Hayashi A; Dansereau J; Hart J
    J Obstet Gynaecol Can; 2010 Dec; 32(12):1167-1171. PubMed ID: 21176329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
    Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
    Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.